Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2451–2500 of 34667
On April 29, 2025 (the “Appointment Date”), the Board of Directors (the “Board”) of AEye, Inc. appointed Doron Simon, effective as of the Appointment Date, as a Class II director
On April 28, 2025, the Board of Directors (the "Board") of the Company appointed Darrell Jackson and Maximillian Sultan as independent directors of the Company, effective immediately.
On April 28, 2025, the Board of Directors (the "Board") of the Company appointed Darrell Jackson and Maximillian Sultan as independent directors of the Company, effective immediately.
Mr. Wodlinger and Mr. Albers were appointed to the Board in connection with the closing of the Merger and in accordance with the terms of the Shareholder’s Agreement
Mr. Wodlinger and Mr. Albers were appointed to the Board in connection with the closing of the Merger and in accordance with the terms of the Shareholder’s Agreement
Craig Donohue will succeed Mr. Tomczyk as Chief Executive Officer of the Company and be elected to the Board, both effective as of the Effective Date.
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Steve Schwab, Joseph Riley, Joel Schubert, Brendan O’Hara, Jeff Parks, Joerg Adams and Rich Ford became directors of the Surviving Corporation.
Steve Schwab, Joseph Riley, Joel Schubert, Brendan O’Hara, Jeff Parks, Joerg Adams and Rich Ford became directors of the Surviving Corporation.
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Steve Schwab, Joseph Riley, Joel Schubert, Brendan O’Hara, Jeff Parks, Joerg Adams and Rich Ford became directors of the Surviving Corporation.
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Steve Schwab, Joseph Riley, Joel Schubert, Brendan O’Hara, Jeff Parks, Joerg Adams and Rich Ford became directors of the Surviving Corporation.
Steve Schwab, Joseph Riley, Joel Schubert, Brendan O’Hara, Jeff Parks, Joerg Adams and Rich Ford became directors of the Surviving Corporation.
Steve Schwab, Joseph Riley, Joel Schubert, Brendan O’Hara, Jeff Parks, Joerg Adams and Rich Ford became directors of the Surviving Corporation.
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
Steve Schwab, Joseph Riley, Joel Schubert, Brendan O’Hara, Jeff Parks, Joerg Adams and Rich Ford became directors of the Surviving Corporation.
Robert Greyber, Jeffrey Parks, Joerg Adams, Ryan Bone, Chad Cohen, Benjamin Levin, Barbara Messing, Karl Peterson and Chris Terrill, representing all of the members of the Board of Directors (the “Board”) of the Company as of immediately prior to the Company Merger Effective Time, each resigned from their positions as members of the Board
On April 30, 2025, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven directors and elected Steven Frank to fill the vacancy created by the enlargement of the Board, effective May 2, 2025 (the “Effective Date”).
appointed Jamie E. Samath to the Board, effective immediately.
In accordance with the Merger Agreement, Kenneth J. Stephon, former Chairman, President and Chief Executive Officer of William Penn and William Penn Bank, has been appointed to serve as a Class C director of Mid Penn, effective as of the Effective Time
Kristin Smith, Rebecca Rettig and Thomas Trowbridge were appointed to the board of directors of the Company.
Kristin Smith, Rebecca Rettig and Thomas Trowbridge were appointed to the board of directors of the Company.
Kristin Smith, Rebecca Rettig and Thomas Trowbridge were appointed to the board of directors of the Company.
On April 28, 2025, in connection with the IPO, Robert Neal, Mark Smith and Eduardo Munemori were appointed to the board of directors of the Company.
On April 28, 2025, in connection with the IPO, Robert Neal, Mark Smith and Eduardo Munemori were appointed to the board of directors of the Company.
On April 28, 2025, in connection with the IPO, Robert Neal, Mark Smith and Eduardo Munemori were appointed to the board of directors of the Company.
On April 28, 2025, the board of directors (the “Board”) of Plum Acquisition Corp. IV (the “Company”) appointed Mr. Aidin Aghamiri to serve as an independent director of the Company, effective April 25, 2025.
Mr. Reiner also expects to resign from the Company's Board of Directors on such date.
Upon commencing employment and taking office as President and Chief Executive Officer, Mr. Cotten will join the Company's Board of Directors as a Class III director with an initial term expiring at the 2028 annual meeting of stockholders.
the Company has accepted the resignation of its Board member and Vice President of Operations, Mohammad Sadrolashrafi, as well as appointing Robert James Kane as a new director and Business Development Officer.
the Company has accepted the resignation of its Board member and Vice President of Operations, Mohammad Sadrolashrafi, as well as appointing Robert James Kane as a new director and Business Development Officer.
On April 29, 2025, Mark Jenkins, a Class II director of Carlyle Secured Lending, Inc. (the “Company”) and a Managing Director of The Carlyle Group, Inc. (“Carlyle”), informed the Company that he is resigning from the Board of Directors of the Company (the “Board”), effective April 29, 2025.
On April 29, 2025, the Board appointed Thomas Hennigan as a Class II director to fill the vacancy created by Mr. Jenkins’ resignation.
On May 1, 2025, Murphy USA Inc. ("Murphy USA") issued a news release announcing the appointment on that date of David C. Haley to Murphy USA's Board of Directors.
appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.
appointed Stuart Duty to the Board, effective May 1, 2025.
Daniel C. Reardon, was appointed by the Board to fill the vacancy resulting from the increase in the size of the Board.
On April 25, 2025, Andrew Dahlem resigned from the Board of Directors of Syra Health Corp. (the “Company”) for personal reasons.
On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.
the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board
the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board
On April 29, 2025, Mark Jenkins, a Class II director of Carlyle Credit Solutions, Inc. (the “Company”) and a Managing Director of The Carlyle Group, Inc. (“Carlyle”), informed the Company that he is resigning from the Board of Directors of the Company (the “Board”), effective April 29, 2025.
On April 29, 2025, the Board appointed Thomas Hennigan as a Class II director to fill the vacancy created by Mr. Jenkins’ resignation.
On April 30, 2025, in connection with the IPO, Sam Lynn, Darla K. Anderson and Constance K. Weaver were appointed to the board of directors of the Company.
On April 30, 2025, in connection with the IPO, Sam Lynn, Darla K. Anderson and Constance K. Weaver were appointed to the board of directors of the Company.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.